Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Pablo Andres OliveraJuan S LasaGiovanni PerettoStephane ZuilySilvio DaneseLaurent Peyrin BirouletPublished in: Alimentary pharmacology & therapeutics (2023)
Available evidence of both JAK inhibitors and S1P modulators indicates a reassuring safety profile of SMDs from the cardiovascular perspective in the overall IBD population. Efforts should be made to identify patients with IBD at a higher risk of cardiovascular events.